Benjamin E. Low

Benjamin E. Low

Auto-generated profile, based on publicly available information

Benjamin E. Low

The Jackson Laboratory, Bar Harbor, ME, USA, 04609

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BWBenjamin Y. Winer
Benjamin Y. Winer
ESElham Shirvani-Dastgerdi
Elham Shirvani-Dastgerdi
YBYaron Bram
Yaron Bram
JSJulie Sellau
Julie Sellau
BLBenjamin E. Low
Benjamin E. Low
Alexander PlossAlexander Ploss
Alexander Ploss
An inbred mouse model for HDV infection can be used to study virally induced immune responses and for testing antiviral therapeutics.

1 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AAAina Karen Anthi
Aina Karen Anthi
AKAnette Kolderup
Anette Kolderup
EVEline Benno Vaage
Eline Benno Vaage
MBMalin Bern
Malin Bern
SBSopisa Benjakul
Sopisa Benjakul
JAJan Terje Andersen
Jan Terje Andersen
Although vaccines are usually given intramuscularly, the intranasal delivery route may lead to better mucosal protection and limit the spread of respiratory virus while easing administration and improving vaccine acceptance. The challenge, however, is to achieve delivery across the selective epithelial cell barrier. Here we report on a subunit vaccine platform, in which the antigen is genetically fused to albumin to facilitate FcRn-mediated transport across the mucosal barrier in the presence of adjuvant. Intranasal delivery in conventional and transgenic mouse models induces both systemic and mucosal antigen-specific antibody responses that protect against challenge with SARS-CoV-2 or influenza A. When benchmarked against an intramuscularly administered mRNA vaccine or an intranasally administered antigen fused to an alternative carrier of similar size, only the albumin-based intranasal vaccine yields robust mucosal IgA antibody responses. Our results thus suggest that this needle-free, albumin-based vaccine platform may be suited for vaccination against respiratory pathogens.

1 December 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
QLQiaoli Li
Qiaoli Li
VPVivek M. Philip
Vivek M. Philip
TSTimothy Stearns
Timothy Stearns
JBJason Bubier
Jason Bubier
Benjamin L. KingBenjamin L. King
Benjamin L. King
JSJohn P. Sundberg
John P. Sundberg

5 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSThomas J Sproule
Thomas J Sproule
RWRobert Y Wilpan
Robert Y Wilpan
BLBenjamin E Low
Benjamin E Low
KSKathleen A Silva
Kathleen A Silva
DRDeepak Reyon
Deepak Reyon
JSJohn P Sundberg
John P Sundberg
Previous work strongly implicated Collagen 17a1 (Col17a1) as a potent genetic modifier of junctional epidermolysis bullosa (JEB) caused by a hypomorphic mutation (Lamc2jeb) in mice. The importance of the noncollagenous domain (NC4) of COLXVII was suggested by use of a congenic reduction approach that restricted the modifier effect to 2–3 neighboring amino acid changes in that domain. The current study utilizes TALEN and CRISPR/Cas9 induced amino acid replacements and in-frame indels nested to NC4 to further investigate the role of this and adjoining COLXVII domains both as modifiers and primary risk effectors. We confirm the importance of COLXVI AA 1275 S/G and 1277 N/S substitutions and utilize small nested indels to show that subtle changes in this microdomain attenuate JEB. We further show that large in-frame indels removing up to 1482 bp and 169 AA of NC6 through NC1 domains are surprisingly disease free on their own but can be very potent modifiers of Lamc2jeb/jeb JEB. Together these studies exploiting gene editing to functionally dissect the Col17a1 modifier demonstrate the importance of epistatic interactions between a primary disease-causing mutation in one gene and innocuous ‘healthy’ alleles in other genes.

26 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSThomas J. Sproule
Thomas J. Sproule
RWRobert Y. Wilpan
Robert Y. Wilpan
JWJohn J. Wilson
John J. Wilson
BLBenjamin E. Low
Benjamin E. Low
YKYudai Kabata
Yudai Kabata
JSJohn P. Sundberg
John P. Sundberg
The Lamc2jeb junctional epidermolysis bullosa (EB) mouse model has been used to demonstrate that significant genetic modification of EB symptoms is possible, identifying as modifiers Col17a1 and six other quantitative trait loci, several with strong candidate genes including dystonin (Dst/Bpag1). Here, CRISPR/Cas9 was used to alter exon 23 in mouse skin specific isoform Dst-e (Ensembl GRCm38 transcript name Dst-213, transcript ID ENSMUST00000183302.5, protein size 2639AA) and validate a proposed arginine/glutamine difference at amino acid p1226 in B6 versus 129 mice as a modifier of EB. Frame shift deletions (FSD) in mouse Dst-e exon 23 (Dst-eFSD/FSD) were also identified that cause mice carrying wild-type Lamc2 to develop a phenotype similar to human EB simplex without dystonia musculorum. When combined, Dst-eFSD/FSD modifies Lamc2jeb/jeb (FSD+jeb) induced disease in unexpected ways implicating an altered balance between DST-e (BPAG1e) and a rarely reported rodless DST-eS (BPAG1eS) in epithelium as a possible mechanism. Further, FSD+jeb mice with pinnae removed are found to provide a test bed for studying internal epithelium EB disease and treatment without severe skin disease as a limiting factor while also revealing and accelerating significant nasopharynx symptoms present but not previously noted in Lamc2jeb/jeb mice.

2 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKathy J. Snow
Kathy J. Snow
ESEthan Saville
Ethan Saville
CHCaleb Heffner
Caleb Heffner
YGYaned Gaitan
Yaned Gaitan
JDJeffrey Duryea
Jeffrey Duryea
SMStephen A. Murray
Stephen A. Murray
With the expansion of therapeutic gene editing technology, small animal models provide essential platforms to evaluate the function of these new approaches in vivo . As part of the Somatic Cell Genome Editing (SCGE) Consortium, we developed next-generation murine reporters that overcome current model limitations and broaden detectable in vivo editing outcomes. These include two mouse models built on the “traffic light” reporter concept. This system enables fluorescent detection of both gene repair (green) and CRISPR-generated indels (red) events following editing by a single guide and either dsDNA or single-stranded oligonucleotide donor. We also generated a third reporter model that efficiently detects A-base editor activity. Reporters were validated in cultured embryos, via germline editing, and through activation in vivo by AAV transduction or direct ribonucleoprotein delivery. Together, these new models provide a valuable resource for improved detection of genome editing events in vivo .